Scienion to Supply Protagen with Microarray Batches for Clinical Validation of Protein Biomarkers
April 22, 2011
Scienion to Supply Protagen with Microarray Batches for Clinical Validation of Protein Biomarkers
The microarray batches will be used in multicenter, clinical validation studies of the company's protein biomarker panels for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation
September 10, 2010 / ProteoMonitor - Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work
April 1, 2011 / ProteoMonitor - Protagen Employs UNIarray Platform to Detect Protein Biomarkers Associated with Infectious Disease
July 9, 2010 / ProteoMonitor - Movers & Shakers
January 15, 2010 / ProteoMonitor - Protagen Hopes to Have Diagnostics Deal Inked by End of 2010, Says CEO
June 30, 2009 / BioArray News